
Antidiabetic Drugs Market by Type (Alpha-Glucosidase Inhibitors, Biguanides, DPP-IV (Dipeptidyl Peptidase) Inhibitors), Disease (Diabetes Mellitus Type 1, Diabetes Mellitus Type 2), Patient - Global Forecast 2024-2030
Description
Antidiabetic Drugs Market by Type (Alpha-Glucosidase Inhibitors, Biguanides, DPP-IV (Dipeptidyl Peptidase) Inhibitors), Disease (Diabetes Mellitus Type 1, Diabetes Mellitus Type 2), Patient - Global Forecast 2024-2030
The Antidiabetic Drugs Market size was estimated at USD 46.93 billion in 2023 and expected to reach USD 51.42 billion in 2024, at a CAGR 10.14% to reach USD 92.32 billion by 2030.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Antidiabetic Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antidiabetic Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Antidiabetic Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alkem Laboratories Ltd., Aristo Pharmaceuticals Pvt. Ltd., Astellas Pharma Inc., AstraZeneca PLC, Biocon Limited, Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Limited, Cipla Limited, Dr. Reddy's Laboratories, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Halozyme Therapeutics, Inc., Johnson & Johnson Services, Inc., Mankind Pharma Ltd., Merck KGaA, Novo Nordisk A/S, Oramed Pharmaceuticals Inc., Pfizer Inc., PHC Holdings Corporation, Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Tonghua Dongbao Pharmaceutical Co., Ltd..
Market Segmentation & Coverage
This research report categorizes the Antidiabetic Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:
Type
Alpha-Glucosidase Inhibitors
Intermediate-Acting Insulin
Diabetes Mellitus Type 1
Adult
Americas
Argentina
California
Australia
Denmark
The report offers valuable insights on the following aspects:
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
- What is the market size and forecast of the Antidiabetic Drugs Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antidiabetic Drugs Market?
- What are the technology trends and regulatory frameworks in the Antidiabetic Drugs Market?
- What is the market share of the leading vendors in the Antidiabetic Drugs Market?
- Which modes and strategic moves are suitable for entering the Antidiabetic Drugs Market?
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
190 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Antidiabetic Drugs Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Rising prevalence of diabetes and increasing obesity among people
- 5.1.1.2. Growing awareness among patients and healthcare professionals regarding the importance of diabetes management
- 5.1.1.3. Initiatives and programs supporting diabetes awareness & treatment
- 5.1.2. Restraints
- 5.1.2.1. Adverse effects associated with antidiabetic drugs
- 5.1.3. Opportunities
- 5.1.3.1. Ongoing research and development for new antidiabetic drugs
- 5.1.3.2. Governments and private companies collaborations to supply inexpensive drugs
- 5.1.4. Challenges
- 5.1.4.1. Stringent regulatory requirements for the approval of antidiabetic drugs
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Antidiabetic Drugs Market, by Type
- 6.1. Introduction
- 6.2. Alpha-Glucosidase Inhibitors
- 6.3. Biguanides
- 6.4. DPP-IV (Dipeptidyl Peptidase) Inhibitors
- 6.5. GLP-1 (Glucagon-like Peptide) Agonists
- 6.6. Insulin
- 6.7.1. Intermediate-Acting Insulin
- 6.7.2. Long-Acting Analog
- 6.7.3. Premixed Insulin
- 6.7.4. Rapid-Acting Analog
- 6.7.5. Short-Acting Analog
- 6.7. Meglitinides
- 6.8. SGLT-II (Sodium Glucose Transport Proteins) Inhibitors
- 6.9. Sulphonylureas
- 6.10. Thiazolidinedione
- 7. Antidiabetic Drugs Market, by Disease
- 7.1. Introduction
- 7.2. Diabetes Mellitus Type 1
- 7.3. Diabetes Mellitus Type 2
- 8. Antidiabetic Drugs Market, by Patient
- 8.1. Introduction
- 8.2. Adult
- 8.3. Geriatric
- 8.4. Pediatric
- 9. Americas Antidiabetic Drugs Market
- 9.1. Introduction
- 9.2. Argentina
- 9.3. Brazil
- 9.4. Canada
- 9.5. Mexico
- 9.6. United States
- 10. Asia-Pacific Antidiabetic Drugs Market
- 10.1. Introduction
- 10.2. Australia
- 10.3. China
- 10.4. India
- 10.5. Indonesia
- 10.6. Japan
- 10.7. Malaysia
- 10.8. Philippines
- 10.9. Singapore
- 10.10. South Korea
- 10.11. Taiwan
- 10.12. Thailand
- 10.13. Vietnam
- 11. Europe, Middle East & Africa Antidiabetic Drugs Market
- 11.1. Introduction
- 11.2. Denmark
- 11.3. Egypt
- 11.4. Finland
- 11.5. France
- 11.6. Germany
- 11.7. Israel
- 11.8. Italy
- 11.9. Netherlands
- 11.10. Nigeria
- 11.11. Norway
- 11.12. Poland
- 11.13. Qatar
- 11.14. Russia
- 11.15. Saudi Arabia
- 11.16. South Africa
- 11.17. Spain
- 11.18. Sweden
- 11.19. Switzerland
- 11.20. Turkey
- 11.21. United Arab Emirates
- 11.22. United Kingdom
- 12. Competitive Landscape
- 12.1. FPNV Positioning Matrix
- 12.2. Market Share Analysis, By Key Player
- 12.3. Competitive Scenario Analysis, By Key Player
- 13. Competitive Portfolio
- 13.1. Key Company Profiles
- 13.1.1. Abbott Laboratories
- 13.1.2. Alkem Laboratories Ltd.
- 13.1.3. Aristo Pharmaceuticals Pvt. Ltd.
- 13.1.4. Astellas Pharma Inc.
- 13.1.5. AstraZeneca PLC
- 13.1.6. Biocon Limited
- 13.1.7. Boehringer Ingelheim International GmbH
- 13.1.8. Cadila Pharmaceuticals Limited
- 13.1.9. Cipla Limited
- 13.1.10. Dr. Reddy's Laboratories
- 13.1.11. Eli Lilly and Company
- 13.1.12. F. Hoffmann-La Roche Ltd.
- 13.1.13. GlaxoSmithKline PLC
- 13.1.14. Glenmark Pharmaceuticals Ltd.
- 13.1.15. Halozyme Therapeutics, Inc.
- 13.1.16. Johnson & Johnson Services, Inc.
- 13.1.17. Mankind Pharma Ltd.
- 13.1.18. Merck KGaA
- 13.1.19. Novo Nordisk A/S
- 13.1.20. Oramed Pharmaceuticals Inc.
- 13.1.21. Pfizer Inc.
- 13.1.22. PHC Holdings Corporation
- 13.1.23. Sanofi S.A.
- 13.1.24. Takeda Pharmaceutical Company Limited
- 13.1.25. Teva Pharmaceutical Industries Ltd.
- 13.1.26. Tonghua Dongbao Pharmaceutical Co., Ltd.
- 13.2. Key Product Portfolio
- 14. Appendix
- 14.1. Discussion Guide
- 14.2. License & Pricing
- FIGURE 1. ANTIDIABETIC DRUGS MARKET RESEARCH PROCESS
- FIGURE 2. ANTIDIABETIC DRUGS MARKET SIZE, 2023 VS 2030
- FIGURE 3. ANTIDIABETIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. ANTIDIABETIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. ANTIDIABETIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. ANTIDIABETIC DRUGS MARKET DYNAMICS
- FIGURE 7. ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
- FIGURE 8. ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
- FIGURE 10. ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2023 VS 2030 (%)
- FIGURE 12. ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 14. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 16. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. ANTIDIABETIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 22. ANTIDIABETIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.